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Abstract
Adoptive therapy using T cells redirected to target tumor- or infection-associated antigens is a promising strategy that has
curative potential and broad applicability. In order to accelerate the screening process for suitable antigen-specific T cell
receptors (TCRs), we developed a new approach circumventing conventional in vitro expansion-based strategies. Direct
isolation of paired full-length TCR sequences from non-expanded antigen-specific T cells was achieved by the establishment
of a highly sensitive PCR-based T cell receptor single cell analysis method (TCR-SCAN). Using MHC multimer-labeled and
single cell-sorted HCMV-specific T cells we demonstrate a high efficacy (approximately 25%) and target specificity of TCR-
SCAN receptor identification. In combination with MHC-multimer based pre-enrichment steps, we were able to isolate TCRs
specific for the oncogenes Her2/neu and WT1 even from very small populations (original precursor frequencies of down to
0.00005% of CD3+ T cells) without any cell culture step involved. Genetic re-expression of isolated receptors demonstrates
their functionality and target specificity. We believe that this new strategy of TCR identification may provide broad access to
specific TCRs for therapeutically relevant T cell epitopes.
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Introduction
Transgenic expression of antigen-specific TCRs has gained
relevance through clinical trials indicating that specific breakup of
tolerance towards tumor-associated auto-antigens can be achieved
by reinfusion of ex vivo-isolated, gene-modified, autologous,
patient-derived T cells. Further clinical data indicate that elevated
TCR binding strength, as a means to elicit site-directed auto-
antigen recognition, can result in enhanced immunogenicity [1–3].
It is generally believed that central tolerance limits the prevalence
of high-avidity TCRs specific for auto-antigens within the
autologous peripheral T cell repertoire. However, there is
evidence that a substantial number of self-reactive TCRs are
recruited into regulatory T cell compartments, which might be
difficult to access with current cell culture based approaches [4,5].
Furthermore, the allo-repertoire has been proposed as an
alternative source of therapeutically efficient TCRs, most
convincingly demonstrated by complete leukemia remissions upon
allogeneic donor lymphocyte infusions (DLIs) [6]. A large
retrospective study of 4643 stem cell transplantations revealed a
pronounced correlation between defined HLA-mismatches and
reduced leukemia relapse. This finding indicates that T cells may
provide better protection if their cognate epitopes are presented by
mismatched HLAs rather than matched HLAs [7]. An explana-
tion for this finding might be the absence of thymic presentation of
mismatch-HLA presented epitopes, which in principle permits the
occurrence of high avidity T cells that recognize tumor-associated
auto-antigens. This assumption is further supported by the finding
that high-avidity T cells from the T cell repertoire of HLA-
mismatched donors can be isolated by in vitro expansion of T cell
clones [8–10].
However, since not all T cells are expandable under similar
conditions, in vitro culture-based protocols limit access to restricted
TCR repertoire compositions [11,12]. This limitation could best
be overcome by direct, ex vivo single-cell sorting of antigen-specific
T cells and subsequent TCR cloning from individual cells, without
the need for any in vitro propagation. In principle, this could be
achieved by combining MHC multimer-staining [13] with single-
cell TCR sequencing.
Although many epitope-specific T cell populations are extreme-
ly rare they can be accurately detected through the combination of
MHC multimer-based pre-enrichment and combinatorial MHC
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e61384
multimer staining technologies [14,15]. However, it has not yet
been possible to combine MHC multimer staining with single-cell
TCR identification, since the simultaneous extraction of both
chains of the hetero-dimeric receptor is technically highly
challenging. Several single-cell-based TCR sequencing efforts
have been described, most using sets of degenerate primers
binding to consensus motifs [16–21] or rapid amplification of
cDNA ends (RACE) PCR [22,23].
Although these strategies resulted in single-cell-derived TCR
sequences, it has not been shown that correct pairing to
functionally reconstruct the receptor of the original cell can be
obtained, e.g. by transgenic re-expression of the identified TCR
chains. There are several technical concerns that require careful
interpretation of sequencing results without further analysis of the
obtained receptor. For example, in the case of consensus primer-
based approaches, V-segment domains are truncated outside the
primer binding sites; since single nucleotide polymorphisms (SNPs)
within V-segments have been described to influence ligand
binding, reliable sequence reconstruction might be limited
[15,24]. Another threat that must be carefully controlled is
potential cross-contamination between samples, as highly sensitive
nested PCR amplifications are prone to contamination and
require extensive protective measures as well as sufficient numbers
of controls. During the establishment of our TCR-SCAN
approach, we indeed had to deal with contaminants that - without
the necessary precautions and permanently implemented in-
process controls - easily could have been misinterpreted as
belonging to a common repertoire present in different donors.
With this report we provide first proof-of-concept evidence that
by combining a novel single-cell sequencing approach and MHC
multimer selection procedures, fully functional TCRs can be
extracted from even extremely rare antigen-specific T cell
populations. This method will give direct and unbiased access to
antigen-specific TCRs independent of T cell differentiation status
or function. We believe that this strategy has broad applicability
and will advance the field of adoptive T cell therapy.
Results
Development of a TCRa/b-specific RACE-PCR with high
efficacy at the single-cell level
We first followed a recently described nested RACE-PCR-based
approach for TCR sequence identification [22]. However, in our
hands this protocol was not sensitive enough for efficient access to
single cells, which forced us to introduce extensive protocol
modifications. We ended up with a procedure as depicted in
Figure 1A. This scheme gives an overview of the entire method.
The different steps are described in more detail later in this
section. Single-cell samples were isolated by FACS-sorting on a
PCR glass wafer from Advalytix, and reverse transcription (RT)
and exonuclease-I digest was directly performed on the slide
before the samples were transferred to 96-well plates to perform
the following steps. We modified the resulting cDNA transcripts by
enzymatically adding a stretch of oligo-dG to the 39 end. This step
generated an artificial priming site upstream of the unknown V-
segment sequence (Fig. S1). We prolonged this artificial priming
site by an additional PCR-step using a primer that binds to the
oligo-dG stretch and has a 51 bp long overhang. We further refer
to this step as anchor PCR.
Pfu-polymerase based enzymes have been shown to digest
primers that bind DNA sequences over a part of their sequence
but not the 39 end. The single stranded 39 end can be degraded
leaving a truncated but completely annealed primer. It was shown
that this exonuclease activity can be blocked by coupling the
nucleotides on the 39 end of a primer over a phosphorothioate
(PTO) group [163]. The primer dC-Anchor PTO (Table S1)
contains a 51 bp long overhanging 59 sequence and otherwise
consists only of cytosine bases, which makes false priming very
likely. Therefore, to prevent the elongation of unwanted priming
events the 39-terminal nucleotide of this primer was coupled over
PTO. Two sequential nested PCRs utilizing the resulting artificial
priming site were added to increase sensitivity and specificity.
Beginning with a reaction volume of 0.5 ml for RT we scaled up
the volume to create optimal reaction conditions for the respective
enzymes in the consecutive steps.
Optimization of different procedures to increase PCR
sensitivity
As shown in Figure. 1B, major improvements in sensitivity were
achieved by using a set of three gene-specific RT primers, each for
a- and b-chain (TCRAC1/2/3 and TCRBC1/2/3), instead of
commonly used standard oligo-dT primers, random hexamer
primers (N6) or a single gene-specific primer. To determine the
sensitivity limit of our protocol we used decreasing cell numbers,
from 1000 cells to a single cell, as a template. we tested different
priming strategies with this experimental approach. Besides
standard oligo-dT RT, we applied two previously published
primers [22] and – each, for a respectively b-chain - three step-like
arranged primers (TCRAC1/2/3 and TCRBC1/2/3). This assay
yielded no clear band, probably because non-specific PCR
interactions increased along with escalating amounts of non-
specific nucleic acids and other cellular components. For
illustration see Figure S1.
We reasoned that residual RT primers, as a potential substrate
for the tailing enzyme, could become the main source of nonsense
products in the following PCR steps. Thus, in line with a previous
report, we confirmed that exonuclease-I digest of residual RT
primers reduced the degree of non-specific priming in serial PCR
amplifications [25]. TCR cDNA at this point is still bound to the
mRNA template and is therefore protected against exonuclease
activity [25]. By combining exonuclease digest of residual RT
primers and use of several serial RT-primers we achieved
amplification of a dense PCR product smear down to five cells.
Nevertheless, at this point the method seemed not sensitive
enough to amplify the TCR from a single cell (data not shown). To
determine, whether the product amplification by the PCR steps
was limiting for the sensitivity we tried to increase the number of
amplification steps. The anchor PCR step initially served to
prolong the artificial priming site; for this reason a single forward
primer was used, resulting in linear product amplification.
However, reverse priming turned this step into an exponential
amplification, which resulted in a striking improvement of
sensitivity (Figure 1C). A schematic overview of the entire priming
strategy is provided in Figure S1. Although we could obtain PCR
products from less cells with this modification single cell samples
still failed to yield a detectable product.
To further refine sensitivity, we again focused on the RT
reaction, as conversion of the minute amounts of easily degradable
mRNA seemed to be a very delicate step in our protocol. We
carefully determined the optimal RT temperature by testing a
range of temperatures between 40uC and 70uC (Figure S2). With
this strategy we succeeded to isolate the TCR from single cells,
however with insufficient efficiency (Fig. 1D). We suspected that
the RT step was most critical, as mRNA is relatively instable. For
this reason we tried to further optimize the RT temperature.
Temperature reduction to 51uC had already slightly improved the
sensitivity, but the most prominent improvement was observed
Single Cell TCR Identification
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e61384
upon addition of a short-term extension at 70uC, despite a rapid
loss of enzyme activity at this temperature (Figure 1D).
Without these important modifications, less than 1% of single-
cell samples resulted in full-length TCR a- and b-chains, whereas,
with the temperature increase from 51uC to 70uC the, approx.
25% of all single-cell samples contained full-length products of the
complete variable part of TCR sequences, including the start
codon. In some cases, several differently sized bands were detected
within one sample. Sequencing of all the bands usually gave
sequence information for the same TCR chain, whereby shorter
bands represented fragments that were truncated in the V-
segment. Samples resulting in PCR bands ranging in size between
500 bp and 750 bp were confirmed to contain complete
sequences. For a more detailed method evaluation, 266 samples
from three different donors were tested in seven independent
experiments. For a-chains, the recovery rates for individual
experiments ranged between 20% and 75%, for full-length b
chains between 25% and 78% and for both chains between 10%
and 50% of all single-cell samples (Figure 1E). More detailed
informations about these experiments are provided in the
following figures.
Determination of efficacy and specificity of single-cell
TCR extraction targeting CMV-specific T cell populations
In order to further validate TCR-SCAN, we FACS-isolated
(under ‘highest purity mode’) single cells from a CMV-specific T
cell population by labeling with HLA-B7/pp65417–426 multimers
(Figure 2A). For each experiment one PCR slide was loaded with
36 single-cell samples. Four samples, each with 10 cells served as
positive controls. To control for potential cross contamination
during the entire process, eight positions were left empty to serve
Figure 1. Optimized RACE-PCR-based approach for TCR sequencing from single cells. (A) Sketch of the basic principle of the novel single-
TCR sequencing strategy. Reverse transcription and exonuclease digest were consecutively done on-slide. Complete reactions were transferred to 96
well plates for tailing, anchor PCR and nested PCR round I and II. Alpha and beta chains were pre-amplified together during anchor PCR and in
separate reactions for nested PCRs I and II. To change the reaction conditions for the first four steps of the protocol, the volume was increased to
create optimal conditions for the subsequent enzyme. For nested PCR round I and II 1 ml of the previous reation volume was transferred to the next
step. (B) Different priming strategies (standard oligo-dT/random hexamers, one gene-specific primer and three gene-specific primers per TCR chain)
were tested with and without extra exonuclease-I digest of residual RT-primers. Decreasing numbers of human T cells, from 1000 to 1 as indicated
served as template. (C)The anchor PCR step is used to prolong the oligo-dG overhang from the tailing step. PCR was tested without reverse primer in
‘‘linear’’ mode and with reverse primer in ‘‘exponential’’ mode of amplification. (D) Temperature switch during reverse transcription was tested. RT at
a constant temperature of 51uC (upper row) was compared with a temperature increase form 51uC for 30 min to 70uC for 20 min (bottom row). (E) In
seven independent single-cell PCR experiments a total number of 266 samples were processed. Numbers of samples yielding a- and/or b- chain
products above the evaluated full-length cut-off size were calculated as a percentage of total samples per experiment. Mean values for all
experiments taken together are indicated by horizontal lines.
doi:10.1371/journal.pone.0061384.g001
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as negative controls. The PCR protocol (Figure 1A) was started
within 48 h after cell isolation, and PCR products were detected
by agarose gel electrophoresis. For sequencing, the PCR products
were gel extracted and subsequently cloned into a carrier plasmid.
Samples yielding both a-and b-chain in full lengths are
highlighted by white boxes (Figure 2B). Within the analyzed T
cell population, we repeatedly detected the same TCR a/b-
pairing (Figure 2C); only once a different sequence was identified,
indicating clonal dominance. We aligned all DNA-sequences of
the TCR that we repetitively isolated and found them to be 100%
identical, which is expected in an antigen-specific T cell
population that is specific for a chronic pathogen (data not
shown). To confirm this interpretation and to exclude cross
contamination, we isolated T cells from the same donor and
expanded clones by limiting dilution. We obtained six T cell
clones, and PCR analysis exclusively identified the same TCR a/
b-pairing as detected in the single-cell PCR-derived samples. The
TCR sequences of the clones were 100% identical to the single-
cell-derived TCR sequences and MHC multimer staining
(Figure 2D).
The second TCR a/b-pairing sequenced from this CMV-
reactive T cell population has been described previously, and the
TCR was identified as part of the public repertoire [26]. These
data confirm that by TCR-SCAN, functional, antigen-specific
TCR sequences can be extracted at single-cell resolution.
Figure 2. Single-cell PCR delivers sequences of functional CMV-specific TCRs. (A) PBMCs from Donor 1 were recovered and stained with
HLA-B7/pp65417–426multimers. Dot plot shows the further analyzed CD8 and MHC multimer double-positive cell population. Cells were pre-gated on
live lymphocytes (propidium iodide-negative, and CD3-positive). (B) TCR SCAN as described in Figure 1 and agarose gel electrophoresis of the
resulting PCR products was performed. The photography shows the agarose gel. Upper row shows a-chain products matched with the respective b-
chains in the lower row. White boxes indicate a- and matched b-chain-products derived from identical single cell samples. (C) The table summarizes
the V- D- J- segment type and amino acid sequences of TCRs identified from CMV-multimer positive T cells in Figure 2A. TCR1A was identified 11
times and TCR 1B was detected once. (D) MHC multimer-positive T cells from the same donor were in vitro expanded and six T cell clones were
successfully maintained. All clones contained TCR1A as confirmed by PCR and sequencing. The left FACS plot shows HLA-B7/pp65417–426 staining and
the right FACS plot shows staining with an irrelevant MHC multimer. (E) PBMCs from donor 2 were recovered and stained with HLA-B8/IE-1199–207
multimers. The dot plot shows the further analyzed CD8 and MHC multimer double-positive cell population. Cells were pre-gated on living
lymphocytes (propidium iodide negative and CD3 positive). (F) TCR SCAN as described in Figure 1 and agarose gel electrophoresis of the resulting
PCR products was performed. Upper row shows a-chain products matched with the respective b-chains in the lower row. White boxes indicate a- and
matched b-chain-products derived from identical single cell samples. (G) The table summarizes the V- D- J- segment type and amino acid sequences
of TCRs identified from CMV-multimer positive T cells in Figure 2E. The respective nucleic acid sequences of all TCR rearrangements all are
summarized in Table S2 and S3. TCR 2A was detected 24 times; TCR 2B only once. (H) PBMCs from Donor 2 were labeled with MHC multimer and
antibody binding to V-segment of TCR 2A Vb6-6. Red line shows MHC multimer-positive cells. Blue line shows total T cells. (I) The identified TCR
sequence from TCR 2A was expressed in Jurkat76 T cells by retroviral gene transfer. Transduced (left FACS plot) and non-transduced (right FACS plot)
Jurkat76 T cells were analyzed for expression of CD3 and MHC multimer binding.
doi:10.1371/journal.pone.0061384.g002
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To demonstrate that complete functional TCR isolation from
single cells is adaptable to T cells with other epitope specificities,
we analyzed CMV-specific T cells from a different donor. T cells
were labeled with HLA-B8/IE-1199–207 multimers and underwent
single-cell sorting (Figure. 2E). Subsequent TCR-SCAN extraction
yielded full-length TCR a/b-pairings in 10% of all isolated single
cells (Figure 2F).
To our surprise, sequencing again revealed mostly identical
TCR a/b-chains among the analyzed samples. The experiment
was repeated to exclude cross contamination and to obtain larger
sample numbers. In total we obtained the sequence of the
dominant TCR in 24 single-cell derived samples (Figure 2G), and
a different TCR a/b-combination was observed in only one
sample. The respective nucleic acid sequences of all TCR
rearrangements all are summarized in Table S2 and S3. Again,
strong clonal dominance characterized the large HLA-B8/IE-
1199–207-specific T cell population. To obtain further evidence for
the presence of a highly dominant T cell clonotype, we analyzed
the original T cell population for its content of Vb6-positive cells.
As shown in Figure 2H, more than 80% of all MHC multimer-
positive T cells expressed the TRBV6-6*01 V-segment, which was
also detected by TCR-SCAN (Figure 2G).
Proof of the antigen specificity of a single cell derived
TCR by gene transfer
To confirm antigen specificity of the TCR sequence isolated on
the single-cell level, we cloned the dominating full-length TCR a-
and b- chain sequences isolated on the single-cell level, we cloned
the dominating full-length TCR a- and b- chain sequences into
the retroviral expression vector pMP71 and transduced the human
T cell lymphoma line Jurkat76. This cell line is deficient in an
endogenous TCR, and therefore CD3 only appears on the cell
surface upon successful transgenic expression of a TCR. More-
over, stable transgenic expression of CD8a co-receptor renders
Jurkat76 cells suitable for MHC class I multimer labeling. As
shown in Figure 2I, upon transduction a substantial portion of the
cells could be stained with MHC multimers.
These data formally prove that MHC multimer-guided single-
cell sorting and subsequent single-cell TCR extraction identifies
antigen-specific and functional TCR sequences.
Direct TCR sequence isolation from a very small and
diverse antigen-specific T cell population
Both CMV-specific T cell populations analyzed above by TCR-
SCAN (Figures 2A and 2E) were quite large and therefore easily
detectable by MHC multimer staining. In addition, they were
extremely oligoclonal, with one dominating TCR sequence. In
such situations, the dominant TCR sequence might also be
extracted from the population using less sensitive in vitro expansion
or direct TCR cloning-based methods. Therefore, we next
analyzed a very small CMV-specific population with a frequency
of less than 0.1% of all CD3+ T cells (Figure 3A). Peripheral blood
mononuclear cells (PBMCs) were stained with HLA-B8/IE-188–96
multimers, and single antigen-specific T cells were isolated by
FACS (Figure 3A). TCR-SCAN yielded paired full-length TCR
a/b-sequences in 20% of all analyzed samples (Figure 3B). The
assay was repeated twice in completely independent experiments
(blood samples were even taken from the donor on separate days);
full-length TCR identification efficacy was very similar and
identical TCR a/b-pairings were identified in both experiments.
We determined full-length sequences for nine different TCRs. For
one TCR, only a non-productive a- (TCR 3G) rearrangements
and for one (TCR 3H) only the b-chain were detected (Figure 3C).
In total we obtained sequence information from 16 single T cells
and could confirm the pairing of several TCR a/b-combinations
in several samples (Figure 3D). The respective nucleic acid
sequences of all TCR rearrangements all are summarized in Table
S2 and S3. Clonal dominance as found in the previously analyzed
CMV-specific T cell populations was not detected. However, a
high degree of similarity within Vb usage and CDR3 regions of
different TCRs was found. CDR3 amino acid sequences separated
for a- and b-chain were subjected to multiple sequence alignment.
The highest degree of sequence similarity was found in the
pairings B,D,E and I. Here a-chain CDR3 domains uniformly
consisted of 12 amino acids, and the associated b-chain CDR3
domains consisted of 15 amino acids. More than 66% and 80% of
all positions were identical for the a-chains and b-chains,
respectively. The grade of resemblance considering similar
chemical properties among different amino acids for both chains
was even 100% (Figure S3).
In order to prove that the obtained sequences indeed translate
to productive T cell receptors, we selected three TCR sequences,
cloned them into retroviral expression vectors and demonstrated
epitope-specific multimer-binding on transduced Jurkat76 cells
(Figure 3E). In summary, these data show that combining MHC
multimer staining with TCR-SCAN can characterize diverse TCR
repertoires even within very small T cell populations.
Functional characterization of a tumor-antigen-specific
TCR isolated ex vivo from an extremely rare population
Encouraged by the finding that even very small antigen-specific
T cell populations can be used for culture-independent identifi-
cation of functional TCR sequences, we asked whether this new
technology might also provide access to extremely rare TCR
sequences with high clinical relevance.
As source for the identification of high-affinity TCR sequences
with specificity for tumor-associated self-antigens, allogeneic donor
lymphocytes (with a mismatch in the target-relevant HLA
restriction) have been explored. In this setting no negative
selection against the target epitope and the associated MHC-
molecule takes places, which in principle enables the prevalence of
high avidity T cells. Despite the presence of a substantial fraction
of alloreactive T cells within allogeneic donor lymphocytes,
defined epitope-specific T cells are extremely rare, as indicated
by enumerations deduced from in vitro cell culture protocols. Two
recent reports could show that – at least in the mouse – it is
possible to visualize rare epitope-specific naı¨ve precursor cells by a
combination of MHC multimer pre-enrichment and combinato-
rial MHC multimer staining [14,15]. Based on these observations,
we hypothesized that it should be possible to derive tumor antigen-
specific TCR sequences from allogeneic donor lymphocytes with
MHC-mismatched MHC multimers, independent of in vitro cell
propagation.
We performed magnetic pre-enrichment of MHC multimer-
binding cells and subsequently labeled the antigen-enriched cell
fraction with a differently labeled HLA-A2/Her2neu369–377 multi-
mer (fluorophore BV421) as published [15]. We performed TCR-
SCAN and were able to isolate a paired full length sequence of one
TCR. Figure 4A shows the FACS staining of the enriched and
double MHC-multimer stained cell fraction as well as the
sequence information we obtained. In order to demonstrate that
this particular TCR sequence is really specific for the selected
Her2/neu369–377 epitope, we performed retroviral transfer into
Jurkat76 cells. Most impressively, A2/Her2/neu369–377 multimer
staining of TCR-transduced cells confirms that we were indeed
able to extract a functional TCR from extremely rare precursor
frequencies of epitope-specific T cells by TCR-SCAN (Figure 4B).
Single Cell TCR Identification
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For further functional testing, we retrovirally transduced the TCR
into human PBMCs and first demonstrated antigen specificity by
the acquisition of MHC-multimer staining (Figure 4C). To show
that this specific ligand binding translates to adequate TCR
signaling, we pulsed T2 cells with 1 mM specific Her2/neu peptide
and co-incubated PBMCs transduced with the newly identified
TCR to measure specific killing of target cells and IFNc secretion
(Figures 4D,E). Even when competing for cell surface expression
with an endogenous TCR up to 20% of all target cells were lysed
in a peptide-specific manner and secretion of IFNc was detectable
down to a peptide concentration of 1029 mM. To finally
demonstrate that this TCR would also recognize real tumor cells
we used the ovarian cancer cell line SKOV-3, which expresses
Her2/neu. This cell line usually is negative for HLA-A2 and thus
cannot present the epitope in question. A HLA-A2 transgenic
version was used to test for IFN-c secretion in response to the
naturally processed and presented epitope, non-transduced A2
negative cells served as a control for specificity. After co-
incubation of 16105 tranduced PBMCs and with an equal
number of the respective tumor cells for 24 h IFN-c secretion was
measured by ELISA. The selective detection of IFN-c in the A2
transgenic sample demonstrates that TCR-4A is able to function-
ally respond to Her2-expressing tumor cells in an MHC and
epitope specific manner.
To test whether our TCR isolation strategy works for a different
auto-antigen, we repeated MHC-multimer enrichment with a
WT1-specific MHC-multimer (Fig S4A). To our surprise the
enrichment yielded 495 cells, which is far more than previously
detected for Her2/neu. We sorted 36 single cells and performed
TCR-SCAN. As previously described for the CMV-specific T cell
populations none of the eight negative controls showed a PCR
product. Interestingly we detected the same TCR pairing
(TCR5B) several times. The complete full-length a- and b-
chain-pairs shown in Figure S4B were sequenced three times.
Beside these two sequences, we repeatedly identified an additional
non-productive b-chain in the same sample (data not shown).
Some samples with only a- or b-chain similarly yielded one of
those three chains. Altogether, three samples contained the
matched full-length a- and b-chain of TCR5B and five more
samples yielded one or two of the three chains. Apart from
Figure 3. Characterization of a small diverse T cell repertoire and transgenic expression of detected TCRs. (A) PBMCs from donor 3
were stained with HLA-B8/IE-188–96 multimers. Dot plot shows the further analyzed CD8 and MHC multimer double-positive cell population. Cells
were pre-gated on living lymphocytes (propidium iodide-negative and CD3-positive). (B) A PCR slide with single antigen-specific T cells from Figure 3A
were FACS-isolated. TCR SCAN as described in Figure 1 and agarose gel electrophoresis of the resulting PCR products was performed. Upper row
shows a-chain products matched with the respective b-chains in the lower row. White boxes indicate samples a- and matched b-chain-products
derived from identical single cell samples. (C) The table summarizes the V- D- J- segment type and amino acid sequences of TCRs identified from
CMV-multimer positive T cells in Figure 3A. In three independent experiments we identified nine different TCRs (TCR 3A-I) (D) Pie chart indicates the
prevalence of identified TCRs from donor 3. Percentages represent incidence of respective TCR divided by total number of positive samples. (E)
Sequences from TCR 3D, 3E and 3G were expressed in Jurkat76 T cells by retroviral gene transfer. Non-transduced (left FACS plot) and transduced
Jurkat76 T cells were analyzed for expression of CD3 and MHC multimer binding.
doi:10.1371/journal.pone.0061384.g003
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Figure 4. Characterization of functionality of a TCR isolated from rare antigen specific T cells. (A) Cells double-positive for HLA-A2/
Her2neu369–377 PE- and BV421-conjugated multimers were FACS sorted. The left FACS plot shows CD8 and MHC multimer staining of the cell fraction
enriched with Her2/neu specific MHC-multimer. The right FACS plot serves as a negative control that was stained in the same way, but for MACS
enrichment only Strep-Tactin backbone was used. Ten single-cell samples were prepared and processed for TCR sequencing. Full-length variable
domain sequences of a- and b-chain full-length variable domain sequences from one specific TCR was identified and is shown in the table. (B)
Sequence from TCR 4A was expressed in Jurkat76 T cells by retroviral gene transfer. Left FACS plot shows A2/Her2/neu369–377 staining and right FACS
plot shows staining with an irrelevant MHC multimer. (C) Sequence from TCR 4A was expressed in human PBMCs by retroviral gene transfer. Left
FACS plot shows A2/Her2/neu369–377 staining and right FACS plot shows staining with an irrelevant MHC multimer. (D) For functional testing 2610
3
peptide-loaded T2 cells (1 mM) labeled with 51Cr were incubated for 4 h with TCR-4A modified PBLs at different effector/target ratios (E/T ratios). After
4 h free 51chrome was quantified in the supernatant. TCR-specificity was controlled by co-incubation with GFP-transduced and non transduced (n.t.)
PBMCs. All conditions were tested in duplicates. (E) For detection of peptide specific release 16105 T2-cells were pulsed with an equal number of
Her2/neu peptide titrated from 1025–1029 M concentration. Equal numbers of transduced (black bar) and non-transduced (grey bar) T cells were co-
incubated for 4 hours and IFNc concentration in the supernatant was measured by ELISA. As positive control T cells were stimulated with CD3/CD28
and as control for peptide specificity T2-cells were pulsed with 1 mM of an irrelevant peptide. IFNc concentration in the supernatant was measured by
ELISA. (F) For detection of tumor specific activity105 tumor cells and equal numbers of transduced (black bar) and non transduced (grey bar) human
PBMCs were co-incubated for 4 hours and IFNc concentration in the supernatant was measured by ELISA. As positive control T cells were stimulated
with CD3/CD28. All conditions were tested in triplicates.
doi:10.1371/journal.pone.0061384.g004
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TCR5B only one different pairing was found (TCR5A). Again, to
confirm antigen-specificity we transduced TCR5A and TCR5B to
human PBMCs by retroviral transfer. MHC multimer staining of
the transduced cells demonstrated a high transduction efficiency
and specificity (Fig. S4C).
Discussion
In this report we present a novel strategy for straightforward
identification of full-length sequences of antigen-specific T cell
receptors with specificity for potentially any therapeutically
relevant T cell epitope. TCR identification at the single-cell level
has multiple advantages over currently available methods. During
in vitro as well as in vivo expansion, the TCR repertoire is shaped
towards defined characteristics, which might limit access to the
therapeutically most effective TCR sequences. For example, it has
recently been reported that chronic infection can lead to dominant
expansion of low-avidity T cell populations, which might be less
effective for immunotherapy [27]. As chronic antigen stimulation
by tumor tissue creates a similar situation for tumor-infiltrating
lymphocytes, in vivo TCR repertoire changes might limit successful
identification of most effective TCR sequences for immunother-
apy. Therefore, the analysis of naı¨ve T cell repertoires for
therapeutic TCR sequences that have not been shaped by chronic
exposition to antigen might be more successful, since a broad
variety of different TCR sequences with diverse antigen recogni-
tion capacities can be expected. TCR-SCAN allows identification
of complete V-segment sequences; therefore, for transgenic re-
expression no reconstruction of variable TCR parts is needed,
which can be complicated by the presence of individual and
functionally relevant SNPs within V-regions. With the protocol
presented in this report, the output of our strategy could be further
improved by accelerating the downstream processing of PCR
products. Especially in combination with next generation
sequencing, this method might be used for large-scale identifica-
tion of T cell receptors pre-defined for antigen-specificity by MHC
multimer labeling. TCR-SCAN could serve to build up a large
library of TCR sequences potentially useful for clinical application.
The frequency of antigen-specific T cells in the naı¨ve murine T
cell repertoire has been determined in earlier reports [14,15].
However, the clonal composition of these cells has never been
explored; such insights should become accessible by our novel
approach. Large amounts of sequence information on TCRs
recognizing the same epitope could help to further elucidate
common rules of binding properties. In earlier reports, the allo-
repertoire was suggested as a promising source of TCRs with high
avidity [8,9,28]. With our novel strategy we can detect antigen-
specific T cells in the allogeneic repertoire (Figure 4) as well as in
the autologous repertoire (Figure S4). As a potential source for
clinically relevant T cell receptors with high avidity for self-derived
tumor antigens, we will explore the regulatory T cell compartment
in more detail. Less prevalent HLA-types should also be analyzed,
further broadening the applicability of adoptive T cell receptor
gene therapy. A limitation of our strategy might be the
dependence on MHC multimer reagents for T cell identification.
However, many of the most prevalent HLA class-I types have
already successfully been used for the generation of MHC
multimers. MHC class II multimers are still less common;
however, recent reports have demonstrated that isolation of
extremely rare antigen-specific cells can be facilitated with MHC
class II multimer reagents. Furthermore, our protocol can in
principle be transferred to any other species, as long as constant
region sequences are available. First experiments in the murine
system show convincing results (data not shown).
Taken together, with this report we describe the first successful
isolation of functional full-length TCR sequences from single T
cells. In combination with MHC multimer-based pre-enrichment
strategies and combinatorial MHC multimer staining, TCR
sequences can be extracted from even extremely rare antigen-
specific T cell populations. We believe that this technology will
foster TCR identification for clinical applications as well as
diagnostics and basic research.
Materials and Methods
Reverse Transcription and PCR
Reverse transcription was performed on an AmpliGrid Slide
from Advalytix. Single-cells were spotted with the Cyclone system
on a MoFlo cell sorter to pre-defined slide positions and were
resuspended in 0.5 ml of 50 mM Tris-HCl (pH 8.3), 75 mM KCl,
3 mM MgCl2, 1,6 mM dNTPs (Roche), 10 mM DTT (Strata-
gene), 0.1 mg/ml BSA, 0.1 mg/ml tRNA (Roche), 0.25% Igepal
CA-630 (Sigma-Aldrich), 0.8 U/ ml RNAsin Plus (Promega),
1 mM reverse transcription primers each (for sequences see Table
S1) and 0.05 rxn/ ml Affinityscript reverse transcriptase. Reverse
transcription was performed for 20 min at 51uC followed by
30 min at 70uC on an AmpliSpeed PCR cycler. For primer
exonuclease I digest, reaction volume was filled up to 1 ml resulting
in a final concentration of 67 mM glycine-KOH (pH 9.5),
6.7 mM MgCl2, 10 mM DTT and 1 U/ ml Exonuclease I
(Fermentas). Exonuclease-I digest was performed for 30 min at
37uC and enzyme was inactivated for 20 min at 70uC on an
AmpliSpeed PCR cycler. For oligo-dG tailing, complete reaction
was transferred to a 96 well plate. Tailing was performed in 5 ml of
a final concentration of 10 mM MgCl2, 1 mM DTT, 10 mM Tris
(pH 7.5) and 2 mM dGTP and 0.75 U/ ml terminal dNTP
transferase (Promega), tailing reaction was performed for 45 min
at 37uC and enzyme was inactivated for 20 min at 37uC on a
Biometra Professional Gradient Cycler. For anchor PCR the
reaction volume was filled up to 25 ml with a final concentration of
16HerculaseII reaction buffer, 0.20 mM dNTPs, 3% formamide,
0.02 rxn/ ml HerculaseII DNA polymerase and 0.5 mM of each
primer (for sequences see Table S1). PCR was performed as
follows: 94uC 3 min for initial denaturation followed by 24 cycles
of 94uC for 15 s, 60uC for 30 s, 72uC for 45 s and 72uC for 5 min
as final extension step. 1 ml of product was transferred to nested
PCR amplification in separate reactions for a- and b- chain. PCR
conditions for nested PCR round I and II were identical to anchor
PCR except for primers (for sequences see Table S1).
Cloning and sequencing
PCR products from single T cell samples were prepared for
sequencing by standard blunt end cloning using CloneJet-kit
(Fermentas). After ligation, plasmid preparation from transformed
DH5a was performed using Pure Yield Mini (Promega). Extracted
Plasmids were Sanger sequenced by the commercial provider
GATC. Sequencing data was analyzed with Vector NTI Advance
and online tools of international ImMunoGeneTics information
system for immunoinformatics (IMGT; http://www.imgt.org).
Retroviral Transduction
PCR products from single-cell PCRs were completed for their
truncated constant region by megaprime PCR. In brief, PCR
products from a- or b-chain were incubated together with
equimolar amounts of PCR product for constant region a- or b-
respectively in a PCR mastermix as in the single-cell PCR
protocol. Reaction mixture was denatured at 94uC and temper-
ature was reduced from 80uC to 40uC at a rate of 0.1u/s to allow
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annealing of overlapping sequences. Extension was performed for
45 s at 72uC. This step was repeated three times before addition of
primers containing restriction overhangs for subsequent cloning.
After addition of primers, 35 cycles of standard PCR were
performed. PCR products were cloned into the retroviral
expression vector pMP71. For transduction of primary T cells
the constant regions of the HER2/neu-specific and WT1-specific
TCRa- and b-chain were replaced by codon optimized murine
sequences harboring mutations to form an additional cystein
bridge. Both TCR chains were combined by a 2A peptide linker
sequence (P2A) and cloned into the retroviral vector MP71-PRE.
Generation of retroviral particles was performed as previously
described [29]. In brief, separate pMP71 expression vectors
containing TCRa- and b-chain or a pMP71 vector with a TCR
cassette, gag/pol plasmid and amphotropic env plasmid were
transfected into HEK 293T cells by calcium phosphate precipi-
tation. Viral supernatant was harvested after 24 h and 48 h and
was transferred to Jurkat76 cells and to human PBLs stimulated
for two days with plate-bound anti-CD3/CD28 antibodies and
100 UI/ml IL-2 (Proleukin, Novartis, Basel, Switzerland). Trans-
duction of target cells was supported by spin inoculation using
retronectin-coated plates (Takara Bio Europe S.A.S., Saint-
Germain-en-Laye, France).
FACS analysis and sorting
FACS antibodies for human cell analysis were CD8 FITC (BD
555366), CD8 PE (BD 555367), CD8 PerCP (BD 345774), CD8
eF450(eBioscience 48-0086-42), CD8 APC (BD 555369), CD3 PE-
Cy7 (eBioscience 25-0038-73) and CD19 PE-A610 (Invitrogen
MHCD19922). For live/dead discrimination, propidium iodide
was used. Samples were analyzed using a CyanLx 9 color flow
cytometer (Beckman Coulter). Cell sorting was performed on a
MoFlo (Beckman Coulter). FACS data was analyzed with FlowJo
v9.5.2 software (Tree Star, Inc.). Strep-Tactin PE and Strep-Tactin
APC were purchased from IBA. Streptavidin BV421 was
purchased from Biolegend. Peptide-MHC multimers were gener-
ated as described [13,30]. In brief, MHC heavy chain was urea
denatured and refolding in the presence of peptide and beta2
microglobulin was enabled by progressive dialysis of detergent.
Complexes were biotinylated by BirA and were purified by FPLC.
Monomeric complexes were multimerized by addition of Strep-
Tactin PE, Strep-Tactin APC or Streptavidin BV421. Ratios
MHC/backbone and staining dilution were separately titrated for
each reagent. HLA-B8 was loaded with CMV IE-1 derived
peptides QIKVRVDMV (88-96) and ELRRKMMYM (199-207).
The HLA-A2 complex was loaded with Her2/neu derived peptide
KIFGSLAFL (369–377) or WT1 specific peptide RMFPNAPYL
(126.134) respectively.
Magnetic cell separation
MACS enrichment with Miltenyi anti-PE nanobeads was
performed on Miltenyi MS-columns according to the manufac-
turers recommendations.
In vitro T cell expansion
T cells were directly FACS sorted into 96 well cell culture plates
containing 1 mg/ml Okt3 antibody (Orthoclone), 1 mg/ml anti
CD28 (BD 340975), 100 U/ml IL-2 (Proleukin), B-LCLs irradi-
ated with 50 Gy and human PBMCs irradiated with 35 Gy. Cells
were kept at 37uC, 95% rel. humidity and 5% CO2 in a total
volume of 200 ml RPMI+, 10% heat inactivated fetal calf serum,
Streptomycin, Penicillin, Gentamycin.
Cells and cell lines
Blood was taken from healthy donors. Written informed consent
was obtained from the donors, and usage of the blood samples was
approved according to national law by the local Institutional
Review Board (Ethikkommission der Medizinischen Fakulta¨t der
Technischen Universita¨t Mu¨nchen). PBMCs were extracted from
whole blood, pre-diluted 1:1 with PBS (pH 7.4), by density
gradient centrifugation for 20 min at 2000 rpm on a layer of
Ficoll.
Jurkat 76 cells were grown at 37uC, 95% humidity, 5% CO2 in
1640 RPMI medium supplemented with 10% fetal calf serum and
100 U/ml penicillin, 100 U/ml streptomycin and gentamycin.
The HER2+/HLA-A22overian cancer cell line SKOV-3
(American Type Culture Collection (ATCC), Manassas, VA,
USA: HTB-77), the HLA-A2+transfected cell line SKOV-3-A2
(supplied by M. L. Disis; University of Washington, Seattle, WA,
USA) and the HEK 293T cell line (ATCC: CRL-11268) were
cultured in DMEM medium with Glutamax I (Life Technologies,
Darmstadt, Germany) supplemented with 10% heat-inactivated
fetal calf serum (inact. FCS; Biochrom AG, Berlin, Germany) and
100 IU/ml of penicillin/streptomycin (P/S; Life Technologies). T
cell medium (TCM) consisting of RPMI 1640 medium with
Glutamax I (Life Technologies) supplemented with 10% inact.
FCS (Pan Biotech, Aidenbach, Germany), 10 mM HEPES, and
100 IU/ml of P/S was used to culture T2 cells (ATCC: CRL-
1992) and primary T cells.
Functional analysis of T cells
TCR-modified PBLs were analyzed in chromium (51Cr) release
assays and interferon (IFNc)- secretion was measured by enzyme-
linked immunosorbent assays (ELISA). To determine cytolytic
activity 26103 peptide-loaded T2 cells (1 mM) labeled with 51Cr
were incubated for 4 h with TCR-modified PBLs at different
effector/target ratios (E/T ratios). T2 cells were pulsed with
HER2369–377: KIFGSLAFL and WT-1126–134: RMFPNAPYL
peptides (Biosynthan, Berlin, Germany). Spontaneous release was
determined using T2 cells incubated without T cells and the transfer
of T2 cells directly to the solid scintillator-coated lumaplates without
incubation produced maximal release values. All samples were run
in duplicates and the specific lysis was calculated as follows:%
specific cytotoxicity = [mean sample release (cpm) - mean
spontaneous release (cpm)]/[mean maximal release (cpm) - mean
spontaneous release (cpm)] 6100. For determination of cytokine
release IFNc was measured after coculture of 16105 TCR-modified
PBLs with the same number of T2 cells pulsed with titrated amounts
of peptide or with tumor cells for 24 h by ELISA (BD Biosciences,
Heidelberg, Germany) according to the manufacturer’s instructions.
Samples were run in triplicates.
Supporting Information
Figure S1 Overview of the TCR-SCAN priming strategy
exemplified for a-chain. For each chain three serially arranged
reverse-transcription-primers (TCRAC 1/2/3) were applied. After
exonuclease digest and 39addition of oligo-dG the next PCR step
(anchor PCR) was performed. Forward primer (dC-anchor-PTO)
bound to the oligo-dG stretch and reverse primer (TCRAC 4)
bound to the TCR constant region. Two subsequent rounds of
nested PCR were performed with forward primers (Adaptor 1and
Adaptor 2) binding to the artificial priming site that was extended
in the previous step. Reverse primers in nested PCR I and II
(TCRAC 5 and TCRAC 6) bound in the constant region. Priming
for b-chain was analogous.
(TIF)
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Figure S2 10 T cells per sample were isolated, and TCR
a-b-chains were amplified by RACE-PCR as described in
Figure 1. Reverse transcription temperature was varied between
samples as indicated.
(TIF)
Figure S3 CDR3 sequences from four closely related
TCR sequences with the same length as shown in
Figure 3E were compared by multiple sequence align-
ment. Grade of identity and similarity was calculated by matrix
blosum62mt2 under Vector NTI.
(TIF)
Figure S4 (A) PBMCs from a healthy donor were labeled
with MHC multimer A2/WT1126–134 and were enriched
by magnetic cell separation. Left FACS-plot shows cell
fraction after enrichment with the MHC multimer backbone and
serves as purity control. Right FACS plot shows cells after
enrichment with functional MHC multimer. (B) Single cells were
sorted for TCR-SCAN and PCR-products were sequenced. Table
shows characteristics of two TCRs from this experiment. TCR5A
was identified once TCR5B three times. (C) TCR5A and TCR5B
were transduced to human PBMCs and MHC-multimer staining
was performed. FACS plots show living lymphocytes after
transduction.
(TIF)
Table S1 All primers that were used in the single cell
PCR protocol are described. The column step indicates
where this primer was used. In addition we show the name we
used and provide the nucleotide sequences.
(TIF)
Table S2 All nucleotide sequences of the a-chain
rearrangements of CMV specific TCRs shown in
Figures 2 and 3 are summarized. The corresponding
sequence can be matched to the information in the respective
figures by the label. We have subdivided the nucleotide sequences
into the different domaints i.e. V- and J segment and the
additional non-germline sequences that have been inserted during
somatic recombination (P- and N- nucleotides).
(TIF)
Table S3 All nucleotide sequences of the a-chain
rearrangements of CMV specific TCRs shown in
Figures 2 and 3 are summarized. The corresponding
sequence can be matched to the information in the respective
figures by the label. We have subdivided the nucleotide sequences
into the different domaints i.e. V-, D- and J-segment and the
additional non-germline sequences that have been inserted during
somatic recombination (P- and N- nucleotides).
(TIF)
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